Abivax SA reported a net loss of €48.47 million [2] for the first quarter of 2026, ending March 31.

The results highlight the financial challenges facing clinical-stage biotechnology companies as they fund expensive long-term trials to bring new therapies to market. While the company maintains a significant deficit, the release of new clinical data provides a potential path toward commercial viability.

During the first quarter of 2026, the Paris-based company generated €1.34 million [1] in revenue. These financial figures were released in early May 2026 alongside updates on the company's primary drug candidate, obefazimod.

Abivax presented three-year interim data from Study 108, a Phase 2a/2b open-label extension trial. The study focused on obefazimod for the treatment of ulcerative colitis, a chronic inflammatory bowel disease. The data indicated that the drug candidate may provide durable remission for patients, a critical milestone for the drug's development process.

Market reaction to the clinical trial data was positive. Abivax shares rose by up to 3.9% [3] following the announcement of the study's lasting effects. The company's focus remains on the progression of obefazimod through the clinical pipeline to secure regulatory approval.

The biotechnology firm also held its annual general meeting on May 11, 2026, to address shareholders and corporate governance. The combination of the quarterly financial report and the interim trial data serves as a progress report for investors tracking the company's ability to transition from a research entity to a commercial producer.

“Abivax SA reported a net loss of €48.47 million for the first quarter of 2026”

The disparity between Abivax's minimal revenue and its substantial net loss is typical for clinical-stage biotech firms, which prioritize research and development over immediate profit. However, the durable remission data from the Study 108 extension is the primary driver of investor confidence, as it suggests the drug candidate is effective over a multi-year period, increasing the likelihood of eventual FDA or EMA approval.